AstraZeneca (LON:AZN) Given Overweight Rating at JPMorgan Chase & Co.

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reissued by investment analysts at JPMorgan Chase & Co. in a research report issued on Tuesday,Digital Look reports.

Several other equities research analysts have also recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating and issued a £150 price objective on shares of AstraZeneca in a research report on Monday, November 10th. Berenberg Bank upped their price target on shares of AstraZeneca from £142 to £145 and gave the company a “buy” rating in a research note on Tuesday, October 21st. Finally, Shore Capital reaffirmed a “buy” rating and issued a £145 price target on shares of AstraZeneca in a report on Thursday, November 6th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and a consensus price target of £138.

AstraZeneca Trading Down 0.1%

Shares of AZN stock traded down GBX 20.31 on Tuesday, reaching £142.04. 2,722,445 shares of the company’s stock were exchanged, compared to its average volume of 59,721,828. The company’s fifty day simple moving average is £135.29 and its 200 day simple moving average is £121.88. AstraZeneca has a 52 week low of GBX 9,573.51 and a 52 week high of £143.12. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The stock has a market capitalization of £220.20 billion, a PE ratio of 23.59, a P/E/G ratio of 0.86 and a beta of 0.17.

Insider Activity at AstraZeneca

In other news, insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of £134.96, for a total transaction of £40,083.12. 0.14% of the stock is owned by insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.